MoonLake's CEO on its looming mid-year pivotal readout in skin disease

Kyle LaHucik

Senior Reporter

MIAMI — MoonLake Immunotherapeutics is expected to have one of the biotech industry’s biggest stock-moving clinical readouts around the middle of this year for a pair …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

MoonLake's CEO on its looming mid-year pivotal readout in skin disease

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Pfizer terminates an early-stage STING agonist trial

Merck diversity leader to retire this summer; Geron seeks commercial chops for next CEO

Inside NYC’s waitlist-only health tech club, where young professionals find both friends and jobs

Lilly-partnered Fauna Bio plans $40M Series A to get into heart failure

Trump blog: Federal agencies must give jobs back to fired probationary workers, judge rules

Obesity drug development—still room to grow

Moon­Lake's CEO on its loom­ing mid-year piv­otal read­out in skin dis­ease

Senior Reporter

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

MoonLake's CEO on its looming mid-year pivotal readout in skin disease